Esther Ramos Boluda *

Autor invitado por SIIC

El trabajo revisa la incidencia y posibles factores de riesgo asociados al síndrome linfoproliferativo tras trasplante intestinal pediátrico

TRASTORNO LINFOPROLIFERATIVO POSTERIOR A TRASPLANTE INTESTINAL PEDIÁTRICO

El síndrome linfoproliferativo es una complicación grave tras el trasplante intestinal en el niño. Su incidencia en nuestro grupo fue algo más del 14%. La mayor parte de nuestros casos estuvieron asociados a la infección por el virus de Epstein-Barr. Fue menos frecuente en el grupo de injertos multiviscerales aunque sin significación estadística.

*Esther Ramos Boluda
describe para SIIC los aspectos relevantes de su trabajo
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AND OTHER MALIGNANCIES AFTER PEDIATRIC INTESTINAL TRANSPLANTATION: INCIDENCE, CLINICAL FEATURES AND OUTCOME
Institución principal de la investigación
*Unidad de Rehabilitación Intestinal. Hospital Universitario la Paz. Madrid. España., Madrid, España
Imprimir nota

Comprar este artículo
Otros artículos escogidos

Referencias bibliográficas
1. Aberg F, Pukkala E, Hockerstedt K, Sankila R, Isoniemi H. Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transpl. 2008;14(10):1428. 2. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117(19):5019. 3. Allen U, Hebert D, Moore D, Dror Y, Wasfy S, Canadian PTLD Survey Group--1998. Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988-97: a Canadian multi-centre experience. Pediatr.Transplant. 2001;5(3):198. 4. Manez R, Breinig MC, Linden P, et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J.Infect.Dis. 1997;176(6):1462. 5. McLaughlin K, Wajstaub S, Marotta P, et al. Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transpl. 2000;6(5):570.6. Stojanova J, Caillard S, Rousseau A, Marquet P. Post-transplant lymphoproliferative disease (PTLD): Pharmacological, virological and other determinants. Pharmacol.Res. 2011;63(1):1. 7. Grant D, Abu-Elmagd K, Reyes J, et al. 2003 Report of the Intestine Transplant Registry: a New Era has Dawned. Ann.Surg. 2005;241(4):607. 8. Bakker NA, van Imhoff GW, Verschuuren EA, et al. Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin.Transplant. 2005;19(3):327. 9. Katz BZ, Pahl E, Crawford SE, et al. Case-control study of risk factors for the development of post-transplant lymphoproliferative disease in a pediatric heart transplant cohort. Pediatr.Transplant. 2007;11(1):58. 10. Leblond V, Choquet S. Lymphoproliferative disorders after liver transplantation. J.Hepatol. 2004;40(5):728. 11. Caillard S, Agodoa LY, Bohen EM, Abbott KC. Myeloma, Hodgkin disease, and lymphoid l emia after renal transplantation: characteristics, risk factors and prognosis. Transplantation 2006;81(6):888. 12. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am.J.Transplant. 2007;7(11):2619. 13. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am.J.Pathol. 1988;133(1):173. 14. Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl.Infect.Dis. 2001;3(2):70. 15. Dharnidharka VR, Ho PL, Stablein DM, Harmon WE, Tejani AH. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr.Transplant. 2002;6(5):396. 16. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003;76(9):1289. 17. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80(7):883. 18. Kahan BD, Yakupoglu YK, Schoenberg L, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005;80(6):749. 19. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am.J.Transplant. 2004;4(2):222. 20. Abu-Elmagd KM, Mazariegos G, Costa G, et al. Lymphoproliferative disorders and de novo malignancies in intestinal and multivisceral recipients: improved outcomes with new outlooks. Transplantation 2009;88(7):926. 21. Nalesnik N, Demetris A.J., Fung JJ, Randhawa P, Zeevi A. Posttransplantation Lymphoproliferative Disorders. 2000;2011(11/09). 22. Bingler MA, Feingold B, Miller SA, et al. Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am.J.Transplant. 2008;8(2):442. 23. Green M, Bueno J, Rowe D et al. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation 2000: 70:593-596. 24. Green M, Soltys K, Rowe DT, Webber SA, Mazareigos G. Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients. Pediatr.Transplant. 2009;13(3):319. 25. Lau AH, Soltys K, Sindhi RK, Bond G, Mazariegos GV, Green M. Chronic high Epstein-Barr viral load carriage in pediatric small bowel transplant recipients. Pediatr.Transplant. 2010;14(4):549. 26. Parker A, Bowles K, Bradley JA, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. Br.J.Haematol. 2010;149(5):675. 27. Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder (bigstar). Am.J.Transplant. 2011;11(2):336. 28. Tsao L, Hsi ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med 2007:131:1209-1218. 29. Gross TG, Savoldo B, Punnett A. Posttransplant lymphoproliferative diseases. Pediatr Clin North Am 2010:57:481-503. 30. Webber SA, Green M. Post-transplant lymphoproliferative disorders and malignancy. In: Fine RN, Webber SA, Oltholff K.M., Harmon WE, eds. Pediatric solid organ transplantation. Second edition ed. Oxford: Blackwell Publishing, 2007: 114.31. Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer 2005;104(8):1661. 32. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006;107(8):3053. 33. Davis JE, Moss DJ. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies. Tissue Antigens 2004;63(4):285

Otros artículos de Esther Ramos Boluda

1. Ramos E, Molina M, Sarría J, Pérez-Moneo B, Burgos E, López-Santamaría M, Prieto G. Chronic rejection with sclerosing peritonitis following pediatric intestinal transplantation. Pediatr Transplantation 2007; 11: 937-941.
2. Prieto G, Pérez-Moneo B, Molina M, Ramos E, Sarría J, Larrauri J, Tovar JA, Fibrosing colonopathy associated with treatment with enteric-coated mesalazine pills. Inflamm Bowel Dis 2009; 15: 1452-1453.
3. Andrés A, Lopez Santamaría M, Ramos E, Sarriá J, Molina M, Hernandez F, Encinas JL, Larrauri J, Prieto G, Tovar JA. Graft-vs-host disease after small bowel transplantation in children. J Ped Surg (2010) 45,330-336.
4. Botija G, Ybarra M, Ramos E, Molina M, Sarría JM, Martinez-Ojinaga E, Andrés AM, López-Santamaría M, Prieto G. Autoimmune cytopenia after pediatric intestinal transplantation: A case series. Transpl Int 2010 23: 1033-1037.
5. Andrés AM, López-Santamaría M, Ramos E, Hernández F, Prieto G, Encinas J, Leal N, Molina M, Sarría J, Tovar JA. The use of sirolimus as a rescue therapy in pediatric intestinal transplant recipients. Pediatr Transplantation 2010; 14: 931-935.
6. Martín-de-Carpi J, Rodríguez A, Ramos E, Jiménez S, Martínez-Gómez MJ, Medina E et al. Increasing incidence of pediatric inflammatory bowel disease in Spain (1996-2009): The SPIRIT registry. Inflamm Bowel Dis. 2013 Jan; 19(1):73-80
7. Feito-Rodríguez M, de Lucas-Laguna R, Gómez-Fernández C, Sendagorta- Cudós E, Collantes E, Beato MJ, Ramos E. Cutaneous Graft Versus Host Disease in Pediatric Multivisceral Transplantation. Pediatr Dermatol. 2013 May; 30(3):335-4.
8. Ramos E, Hernández F, Andrés A, Martínez-Ojinaga E, Molina M, Sarría JM, López Santamaría M, Prieto G. Post-transplant lymphoproliferative disorders and other malignancies after pediatric intestinal transplantation:incidence, clinical features and outcome in a pediatric series. Pediatr Transplantation 2013: 17:472-478.
9. Hernández F, Andrés AM, Encinas JL, Domínguez E, Gámez M, Murcia FJ, Leal N, Martínez L, Molina M, Ramos E, Sarría J, Martínez-Ojinaga E, Prieto G, Frauca E, López-Santamaría M. Preservation of the native spleen in multivisceral transplantation. Pediatr Transplantation 2013:17:556-560.
10. Martín de Carpi J, Rodríguez A, Ramos E, Jiménez S, Martínez-Gómez MJ, Medina E, Navas-López VM. The complete picture of changing pediatric inflammatory bowel disease incidence in Spain in 25 years (1985-2009): The EXPERIENCE registry. J Crohns Colitis 2014.

Para comunicarse con Esther Ramos Boluda mencionar a SIIC como referencia:
erboluda@salud.madrid.org

---

Acerca del trabajo completo

TRASTORNO LINFOPROLIFERATIVO POSTERIOR A TRASPLANTE INTESTINAL PEDIÁTRICO

Título original en castellano
TRASTORNOS LINFOPROLIFERATIVOS POST-TRASPLANTE Y OTRAS MALIGNIZACIONES TRAS TRASPLANTE INTESTINAL PEDIATRICO: INCIDENCIA, HALLAZGOS CLINICOS Y EVOLUCION.

Autores
Esther Ramos Boluda¹, Francisco Hernández Oliveros², Ane Miren Andrés Moreno³, Eva Martínez-Ojinaga Nodal⁴, Manuel Molina Arias⁵, Jesús Sarría Osses⁶, Manuel López Santamaría⁷, Gerardo Prieto Bozano⁸
1 Médico, Unidad de Rehabilitación Intestinal. Hospital Universitario la Paz. Madrid. España., Madrid, España, Médico Adjunto
2 Médico, Hospital Infantil la Paz. Madrid., Médico Adjunto
3 Médico, Hospital Infantil la Paz. Madrid., Médico Adjunto
4 Médico, Hospital Infantil la Paz. Madrid, Médico Adjunto
5 Médico, Hospital Infantil la Paz. Madrid, Médico Adjunto
6 Médico, Hospital Infantil la Paz. Madrid, Médico Adjunto
7 Médico, Hospital Infantil la Paz. Madrid, Jefe de Servicio de Cirugía Pediátrica.
8 Médico, Hospital Infantil la Paz. Madrid, Jefe de Sección de Gastroenterología Inf

Acceso a la fuente original
Pediatric Transplantation
http://www.blackwellpublishing.com/journals/PTR

El artículo se relaciona estrictamente con las especialidades de siicsalud
El artículo se conecta secundariamente con las especialidades